On October 18th, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. announced that it has recently completed a 0.3 billion yuan Series C1 financing, with leading investment from Sino Biopharm, and participation from Pudong Venture Capital, Zhangjiang Haoheng, existing shareholders Qiming Venture Partners and Shanghai Biomedical Fund. Lixin Pharma has recently initiated a Series C2 financing, with the raised funds set to accelerate the clinical progress of pipeline drugs particularly LM-302 and LM-108, support the company's proprietary antibody discovery platform, next-generation ADC technology platform, and dual antibody technology platform.
礼新医药完成3亿元C1轮融资，已启动C2轮融资
Lixin Pharma has completed a 0.3 billion yuan Series C1 financing and has initiated a Series C2 financing.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated